Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746897 · ClinicalTrials.gov registry record · Phase 1
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Hefei TG ImmunoPharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 2
- Study locations
NCT05746897 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Hefei TG ImmunoPharma Co.. The registered enrollment target is 38 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05746897, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Hefei TG ImmunoPharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG Pembrolizumab injection
- DRUG NM1F Injection
Study Locations (2)
Texas
- NEXT Oncology, Dallas - Dallas
Virginia
- Next Oncology, Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05746897
The ClinicalTrials.gov registry entry for NCT05746897 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Hefei TG ImmunoPharma Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab injection is the first listed.
NCT05746897 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05746897 about?
NCT05746897 is a clinical study titled "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors". A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
What is the current status of trial NCT05746897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2023-04-13. Estimated completion is 2027-09-30.
What conditions does trial NCT05746897 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Melanoma, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT05746897?
The interventions under investigation include: Pembrolizumab injection (DRUG), NM1F Injection (DRUG).
Who is sponsoring clinical trial NCT05746897?
This trial is sponsored by Hefei TG ImmunoPharma Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05746897 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.